Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04979910 · ClinicalTrials.gov registry record · Phase 2
Targeting IL-17A for Treatment-Resistant Depression
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04979910 is a Phase 2 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 7 participants.
The verdict
NCT04979910, a Phase 2 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
Interventions
- DRUG Ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2024-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04979910
The ClinicalTrials.gov registry entry for NCT04979910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ixekizumab is the first listed.
NCT04979910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04979910 about?
NCT04979910 is a clinical study titled "Targeting IL-17A for Treatment-Resistant Depression". The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
What is the current status of trial NCT04979910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-08-27. Estimated completion is 2024-04-12.
What interventions are being tested in trial NCT04979910?
The interventions under investigation include: Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT04979910?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.